CS-121 APOC3 Base Editing in Severe Hypertriglyceridemia
A legfontosabb adatok
- Ki végzi
- CorrectSequence Therapeutics Co., Ltd
- Hol
- Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toborzás még nem indult
- Fázis
- Korai 1. fázis
- Résztvevők
- 15 fő, tervezett
- Kezdés
- 2026. jún. 15.
- Várható befejezés
- 2028. júl. 31.
- A vizsgálat típusa
- Beavatkozással járó, 5 csoport
- A vizsgált kezelések
- CS-121
- A regiszteradat frissítve
- 2026. június 18.
Ki vehet részt
- Életkor
- 18 év – 65 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter összes feltétele (24)A regiszter feltételeinek elrejtése
Ki vehet részt
- Male or female participants aged 18 years ≤ age < 65 years
- The serum triglyceride levels of the participants failed to be effectively controlled under the standard treatment regimen (or the medication that is available and tolerable as recommended by clinical practice) and were defined as having at least 3 records of different fasting triglyceride levels ≥ 5.65 mmol/L (500 mg/dL) within 2 years
- The screening period should include at least two different days with a TG level of ≥ 5.65 mmol/L (500 mg/dL), with an interval of at least 7 days
- Able to sign informed consent and comply with the requirements and restrictions specified in the informed consent form and the protocol
- Female participants must meet one of the following: be not of childbearing potential (e.g., documented hysterectomy, bilateral salpingectomy/sterilization, or ≥1 year postmenopausal); or, if of childbearing potential, have a negative pregnancy test at screening and be willing to use strict and effective contraception (e.g., abstinence, pharmacologic, or barrier methods) during the study. Male participants with reproductive potential must agree to use strict and effective contraception (e.g., abstinence, pharmacologic, or barrier methods) throughout the entire post-dose observation period; males without reproductive potential must provide supporting medical history (e.g., post-vasectomy)
Ki nem vehet részt
- Currently participating in other interventional clinical studies, or having an insufficient washout period of less than 5 half-lives or 30 days (whichever is longer) since the last administration of other investigational drugs
- Used antisense oligonucleotide (ASO)-based or small interfering RNA (siRNA)-based lipid-lowering drugs targeting APOC3 within 3 months prior to study drug administration
- Requires long-term use of systemic corticosteroids and steroid drugs and cannot discontinue the medication
- Patients who experienced acute pancreatitis within 4 weeks prior dosing
- History of acute coronary syndrome (ACS) within 6 months before dosing, such as myocardial infarction or unstable angina, or prior coronary revascularization (such as coronary artery bypass grafting), angioplasty or stent implantation
- In the investigator's judgment to be unsuitable for the study drug due to receipt of major surgery within 3 months before dosing
- Concomitant medications/treatments judged by the investigator to affect lipid metabolism, liver and kidney function, coagulation function, or interfere with the efficacy evaluation of the study drug
- Positive results for HBsAg, dual positivity for HCV antibody and RNA, positive for HIV, or positive for Treponema pallidum infection
- Known major organ diseases, mental disorders, Cushing's syndrome, hypothyroidism, history of lymphoproliferative disorders, or malignant tumors in any organ system, which are judged by the investigator as unsuitable for study participation due to potential intolerance to adverse events such as cytokine-Release-Storm
- Any of the following laboratory abnormalities at screening:
- ALT or AST ≥2 × ULN
- Total bilirubin ≥2 × ULN
- eGFR <30 mL/min/1.73 m²
- HbA1c ≥9%
- Absolute neutrophil count < 1.0 × 109/L
- Hemoglobin (female)< 100 g/L, Hemoglobin (male) < 110 g/L
- Platelet count < 100 × 109/L
- Coagulation function abnormalities judged by the investigator as unsuitable for CS-121 administration
- Patients of childbearing potential who are planning pregnancy, breastfeeding, or have fertility plans
Alkalmassági kérdőív
Ez nem döntés: hogy ki vehet részt, azt csak a vizsgálat csapata mondhatja meg.
- Életkor
- Severe hypertriglyceridemia
Hol van ez a vizsgálat?
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
This is an open-label, single-arm, dose-escalation IIT clinical trial to evaluate the safety, tolerability, pharmacodynamics (PD), and pharmacokinetics (PK) of CS-121, an in vivo base editing therapy delivered by lipid nanoparticles targeting APOC3, in adult participants (18-65 years) with Severe Hypertriglyceridemia(sHTG).
A vizsgálat 5 csoportja
- Single Low Dose CS-121A vizsgált kezelés
Participants in this arm will receive a single low dose (0.5mg/kg) of CS-121.
Kezelés: CS-121
- Single Middle Dose CS-121A vizsgált kezelés
Participants in this arm will receive a single middle dose (0.7mg/kg) of CS-121.
Kezelés: CS-121
- Single High Dose CS-121A vizsgált kezelés
Participants in this arm will receive a single high dose (1.0mg/kg) of CS-121
Kezelés: CS-121
- Single selected Lower Dose 1 of CS-121A vizsgált kezelés
Participants in this arm will receive a single selected lower dose 1 of CS-121.
Kezelés: CS-121
- Single selected Lower Dose 2 of CS-121A vizsgált kezelés
Participants in this arm will receive a single selected lower dose 2 of CS-121
Kezelés: CS-121
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Clinical Study to the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of CS-121, an In Vivo Base Editing Therapy Delivered by Lipid Nanoparticles Targeting APOC3 for the Treatment of Severe Hypertriglyceridemia in Adults
- Kérdések a feltételekről
- Forrás: NCT07657780: ki vehet részt
- A regiszteradat frissítve
- 2026. június 18.